Gufic Biosciences has informed that the Board of Directors of the Company at its Meeting held on June 04, 2021 considered and approved the allotment of 1,91,14,506 Equity Shares of the Company of FV of Re 1 each to the Shareholders of Gufic Lifesciences ('Transferor Company' or 'GLPL') pursuant to the Scheme of Amalgamation of Gufic Lifesciences ('Transferor Company') with the Company ('Transferee Company') and their shareholders and creditors; the Audited Financial Results for the quarter and financial year ended March 31, 2021; and recommended Dividend at 10% i.e. Re 0.10 per equity share (Face Value of Re 1 each) for the financial year ended March 31, 2021, subject to the approval of the Shareholders at the ensuing Annual General Meeting.
The above information is a part of company’s filings submitted to BSE.
